Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

IMPORTANCE: Plasma biomarkers of Alzheimer disease may be useful as minimally invasive pharmacodynamic measures of treatment outcomes. OBJECTIVE: To analyze the association of donanemab treatment with plasma biomarkers associated with Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS: TRAILBLAZER...

Descripción completa

Detalles Bibliográficos
Autores principales: Pontecorvo, Michael J., Lu, Ming, Burnham, Samantha C., Schade, Andrew E., Dage, Jeffrey L., Shcherbinin, Sergey, Collins, Emily C., Sims, John R., Mintun, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577883/
https://www.ncbi.nlm.nih.gov/pubmed/36251300
http://dx.doi.org/10.1001/jamaneurol.2022.3392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577883/
https://www.ncbi.nlm.nih.gov/pubmed/36251300
http://dx.doi.org/10.1001/jamaneurol.2022.3392

Ejemplares similares